文献速递临床试验与 GCP基础与转化研究

英夫利西单抗治疗药物监测与标准临床治疗的比较:NOR-DRUM 研究方案

Therapeutic drug monitoring of infliximab compared to standard clinical treatment with infliximab: study protocol for a randomised, controlled, open, parallel-group, phase IV study (the NOR-DRUM study).
PubMed 文献 · Trials · 2020-01-06

NOR-DRUM 是一项随机、开放、平行对照、多中心、全国性、优效性 IV 期研究,分 A、B 两部分。A 部分纳入 400 例开始英夫利西单抗(INX)治疗的患者,主要终点为 30 周缓解;B 部分纳入 450 例维持治疗患者,主要终点为 52 周内疾病恶化。研究旨在评估治疗药物监测(TDM)在多种免疫介导炎症性疾病中的有效性。

要点

  • NOR-DRUM A 纳入 400 例起始 INX 治疗患者,主要终点为 30 周缓解。
  • NOR-DRUM B 纳入 450 例 INX 维持治疗患者,主要终点为 52 周内疾病恶化。
  • 两部位均按 1:1 随机分为 TDM 组与标准治疗组(不知晓药物浓度及抗药抗体状态)。

核心结论

  • NOR-DRUM 旨在评估 TDM 对 INX 治疗患者实现缓解及维持疾病控制的有效性。

研究设计与样本

  • 随机、开放、对照、平行组、比较性、多中心、全国性、优效性 IV 期研究,分 NOR-DRUM A 与 B 两部分。
  • 纳入类风湿关节炎、银屑病关节炎、脊柱关节炎、溃疡性结肠炎、克罗恩病及银屑病患者。
  • 两部位均按 1:1 随机分为 INX 的 TDM 组(干预组)或不知晓药物浓度及 ADAb 状态的标准 INX 治疗组(对照组)。
  • NOR-DRUM A 纳入 400 例起始 INX 治疗患者;NOR-DRUM B 纳入 450 例 INX 维持治疗患者。

关键数值与推荐

  • NOR-DRUM A 主要结局为 30 周时缓解。
  • NOR-DRUM B 主要终点为 52 周研究期间疾病恶化的发生。

临床怎么用

  • 研究结果将为首个评估 TDM 在多种免疫介导炎症性疾病中有效性、安全性及成本效益的试验提供证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Infliximab (INX) and other tumour necrosis factor inhibitors (TNFi) have revolutionised the treatment of several immune mediated inflammatory diseases. Still, many patients do not respond sufficiently to therapy or lose efficacy over time. The large interindividual variation in serum drug concentrations on standard doses and the development of anti-drug antibodies are thought to be major reasons for treatment failures. Therapeutic drug monitoring (TDM), an individualised treatment strategy based on systematic assessments of serum drug concentrations, has been proposed as a clinical tool to optimise efficacy of INX treatment. TDM seems reasonable both from a clinical and an economical point of view, but the effectiveness of this treatment strategy has not yet been demonstrated in randomised clinical trials. The NORwegian DRUg Monitoring study (NOR-DRUM) aims to assess the effectiveness of TDM, both with regard to the achievement of remission in patients starting INX treatment (part A) as well as to maintain disease control in patients on INX treatment (part B). METHODS: The NOR-DRUM study is a randomised, open, controlled, parallel-group, comparative, multi-centre, national, superiority, phase IV study with two separate parts, NOR-DRUM A and NOR-DRUM B. Patients with rheumatoid arthritis, psoriatic arthritis, spondyloarthritis, ulcerative colitis, Crohn's disease and psoriasis are included. In both study parts participants are randomised 1:1 to either TDM of infliximab (intervention group) or to standard treatment with infliximab without knowledge of drug levels or ADAb status (control group). NOR-DRUM A will include 400 patients starting INX therapy. The primary outcome is remission at 30 weeks. In NOR-DRUM B, 450 patients on maintenance treatment with INX will be included. The primary endpoint is occurrence of disease worsening during the 52-week study period. DISCUSSION: As the first trial to assess the effectiveness, safety and cost-effectiveness of TDM in patients receiving TNFi for a range of immune mediated inflammatory diseases, we hope that the NOR-DRUM study will contribute to the advancement of evidence based personalised treatment with biological medicines. TRIAL REGISTRATION: Clinicaltrials.gov, NCT03074656. Registered on 090317.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Syversen SW, Goll GL, Jørgensen KK, et al. Therapeutic drug monitoring of infliximab compared to standard clinical treatment with infliximab: study protocol for a randomised, controlled, open, parallel-group, phase IV study (the NOR-DRUM study). Trials. 2020. PMID: 31907007. doi:10.1186/s13063-019-3734-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。